Inspire Medical Systems (NYSE:INSP) Stock Price Expected to Rise, Truist Financial Analyst Says

Inspire Medical Systems (NYSE:INSP) had its target price lifted by research analysts at Truist Financial from $62.00 to $78.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s target price indicates a potential upside of 15.16% from the stock’s previous close.

A number of other analysts also recently issued reports on INSP. KeyCorp reaffirmed a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Piper Sandler upped their target price on Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. increased their price target on Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Robert W. Baird raised their price target on Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Finally, Zacks Research downgraded Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $68.82.

Inspire Medical Systems Stock Down 1.6%

INSP traded down $1.13 during trading hours on Wednesday, hitting $67.73. 231,847 shares of the company’s stock were exchanged, compared to its average volume of 1,067,780. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 14.69, a PEG ratio of 5.41 and a beta of 0.73. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03. The stock’s 50-day moving average is $65.71 and its two-hundred day moving average is $54.43.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. During the same period in the previous year, the business earned $0.45 EPS. The company’s revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities research analysts anticipate that Inspire Medical Systems will post 1.24 EPS for the current year.

Insider Buying and Selling

In other news, insider Jason Kelly sold 963 shares of Inspire Medical Systems stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This trade represents a 4.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently modified their holdings of INSP. BlackRock Inc. bought a new position in Inspire Medical Systems during the second quarter worth about $211,341,000. Assenagon Asset Management S.A. raised its stake in Inspire Medical Systems by 66.2% in the second quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock valued at $38,561,000 after buying an additional 344,221 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Inspire Medical Systems by 21.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 546,020 shares of the company’s stock valued at $24,358,000 after buying an additional 97,233 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Inspire Medical Systems by 14.4% in the first quarter. Renaissance Technologies LLC now owns 469,968 shares of the company’s stock valued at $24,241,000 after buying an additional 59,200 shares during the last quarter. Finally, ADAR1 Capital Management LLC lifted its position in shares of Inspire Medical Systems by 2,601.3% in the first quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company’s stock valued at $20,900,000 after buying an additional 390,197 shares during the last quarter. 94.91% of the stock is owned by institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.